RetiSpec, developing medical AI for the early detection of Alzheimer’s disease through a simple eye test has secured $10M USD Series A Funding led by iGan Partners and included new strategic investors, Eli Lilly and Company and Topcon Healthcare, Inc., along with existing investors, Gentex Corporation, the Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator, Verge HealthTech Fund, University of Minnesota’s Discovery Capital, Ontario Brain Institute, Centre for Aging + Brain Health Innovation, and private investors.
Read also – [Funding news] CA-based Cowbell Raises $60 Million in Series C Round Funding
This financing brings RetiSpec’s total fundraising to $17M USD. This funding will enable RetiSpec to accelerate the commercialization of its groundbreaking technology aimed at early detection of Alzheimer’s disease.
Read also – [Funding News] Applied Intuition Secures Over $300 Million Funding in Secondary Round
“The closing of this Series A financing is a testament of the significant strides we’ve achieved and marks a major step forward in our mission to enable widespread early and accurate detection of neurodegenerative disease markers with our innovative AI-driven eye test,” said Eliav Shaked, Co-founder and CEO of RetiSpec. “We are thrilled to welcome such strong new investors, alongside existing investors, such as Gentex, who have been key contributors throughout our journey. Together, this investment will allow us to accelerate the commercialization of our AI-driven eye test, which has the potential to transform patient outcomes and enable early, accurate, and equitable access to treatment”.
RetiSpec is currently advancing its regulatory and market entry plans for its first clinically-validated test to predict amyloid burden at the point of care, to aid in the evaluation of individuals for Alzheimer’s disease and other causes of cognitive decline.
It was recently selected from more than 75 global applicants to receive the Davos Alzheimer’s Collaborative inaugural grant for Health System Preparedness to test its technology in optometry settings.
About RetiSpec
RetiSpec is an AI-based company focused on early detection of neurodegenerative diseases through a simple eye exam. RetiSpec’s proprietary AI solution leverages existing retinal imaging cameras to provide a non-invasive, accurate and scalable solution for the early detection of Alzheimer’s disease. RetiSpec is involved in multiple Alzheimer’s and brain health studies in leading hospitals and research networks throughout North America.
